Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
Date:2/19/2009

$152.1 million, which includes revenues from levetiracetam, which was launched in November 2008 and paroxetine extended-release, which was launched in May 2008.

Despite the entrance into the market of additional generic competition in August 2007, sales of fentanyl have increased primarily due to Mylan's ability to continue to supply the market while certain competitors have experienced recall and supply issues.

Total revenues from EMEA were $346.2 million in the current quarter compared to $373.1 million in the same prior year period, a decrease of $26.9 million. This decrease is driven by the effects of foreign currency translation, primarily reflecting the weakening of the Euro versus the U.S. dollar, as revenues in local currencies were higher in the current year. Strong year-over-year growth was experienced in two of the company's largest markets, France and Germany, partially offset by lower sales in the United Kingdom.

Asia Pacific revenues were $129.7 million in the current quarter compared to $170.9 million in the same prior year period, a decrease of $41.2 million. Asia Pacific generates its sales from operations in Australia, Japan and New Zealand. A government-mandated price reduction in Australia, which went into effect in July 2008, combined with the impact of incremental volumes in last year's comparable quarter due to initial shipments to a new distribution partner, resulted in lower year-over-year sales in that country. These factors more than offset an increase in revenues in Japan. In addition, Asia Pacific revenues were negatively impacted by the effect of foreign currency translation.

Specialty, consisting of Mylan's Dey business, which focuses on the development, manufacturing and marketing of specialty pharmaceuticals in the respiratory and severe allergy markets, reported third-party sales of $77.5 million compared to $102.1 million for the three months ended De
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... owners drew up their lists of New Year,s resolutions for 2014, ... my furry companion." Nowadays there are pet salons, dog and cat ... the little canine or feline darlings along wherever mommy or daddy ... toys at the pet store. But anyone who has ever lived ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL) today ... for its asthma management product, Aridol., "This ... Pharmaxis Chief,Executive Officer Dr Alan Robertson. "Korea is ... Aridol in Asia. There are an estimated 2.5 ...
... cheaper and more efficient is the aim of a ... and Q1 NanoSystems. The university and the company, based ... exclusive licensing of a package of jointly-owned intellectual property ... The agreement covers inventions that enable manufacture of very ...
... GPRO ) announced today that the Company will ... on Wednesday, February 13,2008 at approximately 4:00 p.m. Eastern ... call at 4:30 p.m. ET hosted by Henry L. ... senior,vice president, finance, and chief financial officer., The ...
Cached Biology Technology:Pharmaxis' Aridol Gains First Asian Approval 2Solar energy technology licensed 2Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call 2
(Date:4/17/2014)... A drug under clinical trials to treat tuberculosis could ... that act against various bacteria, fungal infections and parasites, ... of Illinois chemists and collaborators. , Led by U. ... the different ways the drug SQ109 attacks the tuberculosis ... other pathogens from yeast to malaria and how ...
(Date:4/17/2014)... 2014. Kessler Foundation has been named awardee of ... Department of Defense Spinal Cord Injury Research Program. ... the randomized, double-blinded, controlled, multi-site clinical trial, which ... strength after spinal cord injury. Dr. Forrest is ... at Kessler Foundation. Two additional sites will participate ...
(Date:4/17/2014)... Down syndrome - or trisomy 21 - is the ... from a chromosomal abnormality where cells of affected individuals ... the human genome). A study conducted by Stylianos Antonarakis ... and Development at the University of Geneva (UNIGE) Faculty ... on how the extra chromosome 21 upsets the equilibrium ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... is fit and well? This is a question which has ... have come up with the answer - using DNA chips. ... UK universities are developing a DNA chip to monitor the ... save the salmon industry thousands and also help conserve dwindling ...
... notable effect on rates of pregnancy and abortion, according to ... emergency contraception is questioned by Professor Anna Glasier, director of ... NHS Trust, Edinburgh, who says it does help some women ... pregnant. , Use of this form of contraception has increased ...
... broccoli was good for you, she just didn't know it ... you and that it contains compounds known to lessen the ... how these compounds work and what their specific targets may ... at the University of Virginia School of Medicine. , ...
Cached Biology News:Special chip provides better picture of salmon health 2Special chip provides better picture of salmon health 3
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
... Ciphergens ProteinChip System, Series 4000 incorporates the ... researchers and biologists in biomarker research. The ... fastest route for converting biomarker discoveries to ... The Series 4000 is designed to fit ...
Gelatin 100 mm Culture Dishes...
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
Biology Products: